Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
P12644

UPID:
BMP4_HUMAN

ALTERNATIVE NAMES:
Bone morphogenetic protein 2B

ALTERNATIVE UPACC:
P12644; Q9UM80

BACKGROUND:
The Bone morphogenetic protein 4, with alternative name Bone morphogenetic protein 2B, plays essential roles in embryonic development and tissue formation. It initiates signaling pathways crucial for neurogenesis, vascular and skeletal development, and angiogenesis by binding to specific receptors, thereby activating SMAD1/5/8 and non-canonical pathways like ERK/MAP kinase and PI3K/Akt. This protein's ability to modulate cellular responses highlights its significance in developmental biology.

THERAPEUTIC SIGNIFICANCE:
Given BMP4's critical role in conditions such as Microphthalmia, syndromic 6, and Non-syndromic orofacial cleft 11, targeting this protein could offer novel therapeutic avenues. The exploration of Bone morphogenetic protein 4 in drug discovery holds promise for developing treatments for a range of developmental disorders and enhancing regenerative medicine strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.